Purpose or Objective: For the locally advanced prostate cancers (LAPC) dose escalated external beam Radiotherapy (dEBRT) with androgen deprivation therapy (ADT) for 2-3 years is the current standard of care. The role of radical prostatectomy (RP) for high-risk prostate cancer is still debated. Better outcomes with RP as compared to dEBRT especially <69 years of age has been reported. However there is no data available from India to compare dEBRT and RP. We did a retrospective study to compare dEBRT or RP in patients with LAPC.
Conclusion:
UI is the complication associated with RP. Dose escalated IGRT for LAPC is no different from RP in terms of bRFS however there was a trend towards better CSS and distant DFS. Further long term follow up is needed to assess the effect on distant disease free survival and CSS. Purpose or Objective: Radical cystectomy (RC) and pelvic lymph-node dissection (PLND) are standard procedures in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR) is a common early event associated with a poor prognosis. The aim of this study is to evaluate adjuvant radiotherapy (RT) for pathological high-risk MIBC.
Material and Methods:
We retrospectively reviewed data from patients treated by RC from 3 institutions. Inclusion criteria were MIBC, histologically proven urothelial carcinoma treated by RC and adjuvant RT. Patients with conservative surgery were excluded. LRR free-survival, overall survival (OS) and metastasis-free survival (MFS) were evaluated. Acute toxicities were recorded according to CTCAE V4.0 scale.
Results:
Between January 2000 and December 2013, 57 patients with a median age of 66 years (45-84) were included. Post-operative pathological staging was pT2, pT3 and pT4 in 16%, 44%, and 39%, respectively. PLND revealed 28% of pN0, 26% of pN1 and 42% of pN2. For 2 patients, no PLND was performed. Median number of lymph-nodes retrieved was 10 (2-33). Forty-eight patients (84%) received platin-based chemotherapy, 7 in neo-adjuvant and 41 in adjuvant setting. For RT, clinical target volume 1 (CTV 1) encompasses pelvic lymph nodes for all patients. CTV 1 also included cystectomy bed for 37 patients (65%). Median dose for CTV 1 was 45 Gy (4-50). Dose complement of 16 Gy (5-22) corresponding to CTV 2 was achieved in 53 of cases, depending on pathological features. Intensity Modulated RT was performed in one third of patients. With a median follow-up of 40.4 months, LRR occurred in 8 patients (14%) that appeared concomitantly with metastasis in two-third of cases. Three-year loco-regional free survival, MFS and OS were 45% (IC 95% 0.30-0.60), 39% (IC 95%, 0.25-0.52) and 49% (IC 95%, 0.33-0.63), respectively. Acute grade ≥3 toxicities were observed in 5 patients (9%). One patient died with intestinal fistula in septic context. No survival or toxicity predictive factor was identified.
Conclusion:
Adjuvant radiotherapy for pathological high-risk MIBC is safe and may have oncological benefits. Thus, new prospective trials evaluating this approach with modern RT techniques should be undertaken. Material and Methods: Our inclusion strategy was to first identify patients treated for the relevant ICD-10 codes. A number of 270 patients matched the ICD-10 criteria (see CONSORT diagram). In a second step, patients that were treated at other sites than the pelvis, treated for distant metastasis, patients suffering from renal cell cancer and cancer of the renal pelvis were excluded. In a third step patients treated with radiation doses that are typical for palliation (<45Gy) were excluded from the analysis. After this, a number of 57 patients remained at the database for further analyses. All patients were treated for recurrent urothelial cancer of the bladder, of the ureter or of the urethra. All patients were treated using 3D conformal radiation therapy. Mean prescribed dose was 54.22Gy (range 45-72Gy).
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Mean time from first diagnosis to radio(chemo)therapy was 22.9 months (range one week to 276 months). In 24 cases (42.1 %) a concomitant chemoradiotherapy was applied.
Results: Mean survival from the beginning of radiation treatment was 39.2 months (CI 95 % 24.7 -53.69 months; median survival 14 months CI 95% 6.8 -21.1). Tumor stage at the time of surgical intervention did not show an impact on overall survival (p= 0.96). Patients were divided into three subgroups, depending on the surgical intervention prior to radiation therapy: most patients were treated by TUR(n= 38) before the indication to radiation therapy was made, 13 patients had a TUR followed by cystectomy in their further history and in 6 patients early cystectomy was the first type of treatment. Patients treated with TUR-B followed by radiotherapy were significantly older compared to patients with cystectomy before radiotherapy and were less likely to receive chemotherapy. There was no significant difference for the length of the interval between first treatment and radiotherapy for the three groups. Despite of this, type of surgical procedure before radiotherapy did not show an impact on overall survival (p = 0.86).
Conclusion:
In our study we found equal survival of patients treated with (chemo)radiotherapy after TUR-B only compared to patients with cystectomy prior to radiotherapy. Younger age and more concomitant chemotherapy of the latter group was not able to prolong survival. Further, the presence of extracapsular extension (ECE) has been shown prospectively to be a criterion for the addition of chemotherapy to postoperative radiation therapy. Limited data exist regarding ECE in inguinal or pelvic LNs from primary penile cancer (PeCa).
EP-1388

Material and Methods:
We retrospectively analyzed outcomes of patients with PeCa and pathologically confirmed LN across four international tertiary referral centers. Clinical and demographic characteristics were compared of outcomes (local control and overall survival) by ECE status and between those who had received adjuvant RT or not.
Results:
Records of 93 patients were available. Median age at time of LND was 65.3 years (range 35.9-90.2 years). Median follow up was 9.4 months . The median number of involved ILNs was 4 (range 1-12), and median PLNs positive was 2 (range 1-21). 72% of patients had ECE in the inguinal area and 49% had ECE in the pelvis. Infield failure occurred in 26/87 sites with ECE and 8/64 sites without ECE (p = 0.015). In the presence of ECE, patients receiving RT experienced infield failure in 17/50 cases and in 10/38 patients not receiving RT (P=NS). Absent ECE, patients failed infield in 5/40 cases after RT and 3/24 cases without RT (p=NS). RT was not associated with improved OS (p=0.073) or recurrence (p=0.492) on multivariate analysis. Chemotherapy was significant on multivariate analysis for recurrence (p = 0.009) but not survival (p=0.334).
